Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer

Joshua D. Palmer, Nicholas G. Zaorsky, Matthew Witek, Bo Lu

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


The elucidation of driver mutations involved in the molecular pathogenesis of cancer has led to a surge in the application of novel targeted therapeutics in lung cancer. Novel oncologic research continues to lead investigators towards targeting personalized tumor characteristics rather than applying targeted therapy to broad patient populations. Several driver genes, in particular epidermal growth factor receptor (EGFR) and ALK fusions, are the earliest to have made their way into clinical trials. The avant-garde role of genomic profiling has led to important clinical challenges when adapting current standard treatments to personalized oncologic care. This new frontier of medicine requires newer biomarkers for toxicity that will identify patients at risk, as well as, new molecular markers to predict and assess clinical outcomes. Thus far, several signature genes have been developed to predict outcome as well as genetic factors related to inflammation to predict toxicity.

Original languageEnglish (US)
Pages (from-to)387-398
Number of pages12
JournalJournal of Thoracic Disease
Issue number4
StatePublished - 2014

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer'. Together they form a unique fingerprint.

Cite this